TICKERNERD
Menu
BBNXBBNXHealthcare · Medical Devices

BBNX Stock Forecast: Beta Bionics, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$17
−0.12% on the day

The 12 Wall Street analysts covering Beta Bionics, Inc. hold a median 12-month price target of $20 — +20.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 40 of 100 as at 12 Sept 2026 — in the lower half.

Market cap
$745.5M
Ticker Nerd rank
40 / 100
Median analyst target
$20
Analysts covering
12
Revenue$32.0M+37.8% y/y
Operating income−$25.6M
Net income−$23.4M
Free cash flow−$15.7M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−16.8%
1M
−6.0%
YTD
−45.6%
1Y
−34.6%
From 52W high
−48.2%
From 52W low
+87.0%
$9
$32
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

BBNX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Beta Bionics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
40 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
67
Growth
62
Accruals
56
Size
49
Value
42
Momentum
40
Issuance
36
Volatility
35
Quality
30

Revisions (67): Analysts have, on balance, been raising their forecasts.

Quality (30): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

BBNX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BBNX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$15$20$25$30Oct 25Jan 26Apr 26Jul 26BBNXHigh $30Median $20Low $14

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says12 analysts
8 Buy4 Hold0 Sell
Low $14Median $20High $30

The green dot is the last close — the median target sits +20.7% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
21 Aug 2026William BlairInitiatesMarket Perform—
28 July 2026UBSAssumesBuy$22
15 July 2026Goldman SachsMaintainsBuy—
15 July 2026Goldman SachsMaintainsBuy$17 → $19
13 July 2026Truist SecuritiesMaintainsBuy$18 → $22
13 July 2026Truist SecuritiesMaintainsBuy—
27 May 2026Goldman SachsMaintainsBuy—
18 May 2026B of A SecuritiesMaintainsNeutral—
22 Apr 2026Leerink PartnersMaintainsOutperform—
22 Apr 2026StifelMaintainsBuy—
15 Apr 2026Truist SecuritiesMaintainsBuy—
9 Apr 2026Goldman SachsMaintainsBuy—
18 Feb 2026BairdMaintainsNeutral—
18 Feb 2026StifelMaintainsBuy—
4 Feb 2026StifelMaintainsBuy—
2 Feb 2026Truist SecuritiesMaintainsBuy—
27 Jan 2026TD CowenInitiatesHold—
9 Jan 2026Lake StreetMaintainsBuy—
5 Jan 2026B of A SecuritiesMaintainsBuy—
18 Dec 2025Truist SecuritiesMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BBNX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

BBNX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Beta Bionics, Inc. returned −34.6% against +17.5% for the S&P 500, dividends included.

BBNX vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Oct 25Jan 26Apr 26Jul 26BBNXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

BBNX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

Beta Bionics, Inc. (BBNX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−9.2×

Cheaper than 92% of US stocks

Price / sales
6.3×

Cheaper than 21% of US stocks

Price / book
2.9×

Cheaper than 34% of US stocks

EV / EBITDA
−7.1×

Cheaper than 82% of US stocks

Growth & margins
Revenue growth (YoY)
37.8%

Higher than 82% of US stocks

Earnings growth (YoY)
37.8%

Higher than 70% of US stocks

Gross margin
59.0%

Higher than 72% of US stocks

Operating margin
−79.9%

Higher than 15% of US stocks

Net margin
−61.3%

Higher than 9% of US stocks

Returns & dividend
Return on equity
−26.2%

Higher than 29% of US stocks

Return on assets
−16.7%

Higher than 22% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Beta Bionics, Inc. (BBNX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Beta Bionics, Inc. has a market value of $745.5M and an enterprise value of $571.5M.

  • Revenue in the twelve months to 30 June 2026: $119.0M. The latest quarter grew 37.8% year on year.

  • Net income over the same four quarters: −$73.0M, a −61.3% net margin.

  • Diluted earnings per share, trailing twelve months: $−1.65.

  • Free cash flow in the twelve months to 30 June 2026: −$61.4M.

  • Shares outstanding: 45.0M.

  • Trailing P/E: −9.2×; forward P/E: −7.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Beta Bionics, Inc. employs 420 people — $283K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

BBNX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
BBNXBeta Bionics, Inc.$745.5M
40
VREXVarex Imaging Corp.$773.8M
80
QDELQuidelOrtho Corp.$803.3M
35
SIBNSI-BONE, Inc.$811.8M
74
AVRAnteris Technologies Global Corp.$811.9M
22
AHCOAdaptHealth Corp.$823.6M
43
SSIISS Innovations International, Inc.$640.9M
21

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Beta Bionics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BBNX news & analysis

Beta Bionics Announces FDA Clearance of Mint™, the Company's Transformative Patch Pump, and Unveils 3D Intelligence™ as its Next-Generation Insulin Dosing Algorithm

GlobeNewsWire · 14 Sept 2026positive

Beta Bionics announced U.S. FDA clearance of its Mint patch pump, which features a reusable and disposable architecture, CGM integration, and smartphone control for iOS and Android. The company also unveiled 3D Intelligence, its next-generation insulin dosing algorithm.

Why it matters — FDA clearance of Mint broadens Beta Bionics' addressable insulin delivery market, potentially expanding its reach among people with diabetes seeking a patch pump form factor.

Senseonics Announces Strategic Partnership with Beta Bionics to Integrate Eversense® 365 with the iLet® Bionic Pancreas

GlobeNewsWire · 14 Sept 2026positive

Senseonics announced a strategic partnership with Beta Bionics to integrate its Eversense 365 continuous glucose monitoring system with the iLet Bionic Pancreas. The integrated system is planned for commercial launch in Q4 2026, bringing the one-year implantable CGM to the iLet user community.

Why it matters — The partnership broadens the iLet Bionic Pancreas's compatibility with a year-long implantable CGM, potentially simplifying diabetes management for patients using the device.

BBNX Investors Have Opportunity to Lead Beta Bionics, Inc. Securities Fraud Lawsuit

PRNewsWire · 13 Sept 2026negative

Rosen Law Firm announced a class action securities fraud lawsuit on behalf of Beta Bionics, Inc. (BBNX) purchasers who bought common stock between July 30, 2025 and February 24, 2026. The action covers shareholders during that stated Class Period.

Why it matters — The lawsuit signals potential legal and financial exposure for the company, which BBNX shareholders would watch closely.

Kaplan Fox Encourages Investors of Beta Bionics, Inc. (NASDAQ: BBNX) Who Suffered Losses to Contact the Firm Before November 3, 2026

GlobeNewsWire · 12 Sept 2026negative

Kaplan Fox & Kilsheimer LLP announced that a class action lawsuit has been filed against Beta Bionics, Inc. on behalf of investors who purchased or otherwise acquired its common stock between July 30, 2025 and February 24, 2026. The firm is encouraging affected investors to contact them before November 3, 2026.

Why it matters — A class action lawsuit has been filed against Beta Bionics covering a defined class period, which is a significant legal development for the company and its investors.

Deadline Approaching: Beta Bionics, Inc. (BBNX) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith

Business Wire · 11 Sept 2026negative

Law Offices of Howard G. Smith reminded Beta Bionics investors of the November 3, 2026 deadline to file a lead plaintiff motion in a securities case. The case concerns investors who purchased BBNX securities between July 30, 2025 and February 24, 2026.

Why it matters — The notice alerts BBNX shareholders to an active securities class action and an approaching deadline for those who suffered losses during the stated period to participate.

FAQ

Frequently asked questions about BBNX stock

What is the BBNX stock price forecast for 2026-2027?

The 12 Wall Street analysts covering Beta Bionics, Inc. have a median 12-month price target of $20, with estimates ranging from $14 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is BBNX stock a buy right now?

Of the 12 analysts covering Beta Bionics, Inc., 8 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Beta Bionics, Inc. 40 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BBNX?

As at 12 Sept 2026, Beta Bionics, Inc. ranks 40 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (67 of 100).

Will BBNX stock go up?

No one can know that. What the data says: the median 12-month target from 12 analysts implies +20.7% from the last close, and Ticker Nerd's factor model ranks Beta Bionics, Inc. 40 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the BBNX stock forecast for 2030?

No analyst covering Beta Bionics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BBNX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $14 to $30 over the next 12 months.

How has BBNX stock performed over the past year?

Beta Bionics, Inc. returned -34.6% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Beta Bionics, Inc. do?

Beta Bionics Inc. is a commercial-stage medical device company focused on automated insulin delivery for people with insulin-requiring diabetes.

What is the latest news on BBNX?

The most recent item we track (GlobeNewsWire, 14 Sept 2026): "Beta Bionics Announces FDA Clearance of Mint™, the Company's Transformative Patch Pump, and Unveils 3D Intelligence™ as its Next-Generation Insulin Dosing Algorithm". Beta Bionics announced U.S. FDA clearance of its Mint patch pump, which features a reusable and disposable architecture, CGM integration, and smartphone control for iOS and Android. The company also unveiled 3D Intelligence, its next-generation insulin dosing algorithm.

Company

About Beta Bionics, Inc.

Beta Bionics Inc. is a commercial-stage medical device company focused on automated insulin delivery for people with insulin-requiring diabetes. Its core product, the iLet Bionic Pancreas, is designed to simplify day-to-day diabetes management by using adaptive closed-loop algorithms to determine insulin dosing. Beta Bionics offers systems and related solutions for adults and children with type 1 diabetes, alongside supporting software and connected tools that help streamline treatment workflows. The company operates in the diabetes technology and medical devices markets, where it addresses the needs of patients, caregivers, and healthcare providers seeking more integrated insulin management solutions. Headquartered in Irvine, California, Beta Bionics plays a role in advancing device-based diabetes care through commercially available products centered on automated insulin delivery.

CEO Mr. Sean T. Saint PE · 420 employees · United States · https://www.betabionics.com